Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes

European Journal of Haematology

Volumn 66, Issue 1, 2001, Pages 31-36

  Voulgari, Paraskevi V ^a   Hatzimichael, Eleftheria Ch R ^a   Tsiara, Stavroula ^a   Tzallas, Christos ^a   Drosos, Alexandros A ^a   Bourantas, Konstantinos L ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Department of Haematology ^*  (Greece)

Author keywords

Anemia; Anti epo autoantibodies; Myelodysplastic syndromes; Response; rHuEpo

Indexed keywords

AUTOANTIBODY; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD CELL COUNT; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA;

AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOANTIGENS; BLOOD CELL COUNT; BLOOD TRANSFUSION; COMBINED MODALITY THERAPY; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; ISOANTIBODIES; ISOANTIGENS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECOMBINANT PROTEINS; TREATMENT FAILURE;

EID: 0035145429     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.00336.x     Document Type: Article

References (46)

1. Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment
2. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome bone marrow cells
3. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients wit myelodysplastic syndromes
4. Myelodysplastic syndromes
5. The French-American-British (FAB) co-operative group: Proposals for the classification of the myelodysplastic syndromes
6. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes
7. Erythropoiesis in myelodysplastic syndrome: Expression of receptors for erythropoietin and kit ligand
8. Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes
9. Ineffective erythropoiesis in myelodysplastic syndromes: Correlation with Fas expression but not with lack of erythropoietin receptor signal transduction
10. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome
11. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS)
12. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long term follow-up of 71 patients
13. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy
14. Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: Proposal for a predictive model
15. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Indetification of a subgroup of responders
16. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin
17. Brief report: Autoantibodies against erythropoietin in a patient with pure red-cell aplasia
18. Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythamatosus: Correlation with anemia
19. Pure red cell aplasia as presentation of systemic lupus erythematosus: Antibodies to erythropoietin
20. Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus type 1-related anemia
21. Human preleukemia
22. Myelodysplasia
23. Hypoplastic myelodysplastic syndrome. Incidence, morphology, cytogenetics and prognosis
24. Ineffective hematopoiesis and apoptosis in myelodysplastic syndromes
25. Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines
26. Increased levels of soluble interleukin-2 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes
27. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin
28. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome
29. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death
30. Evidence for involvement of tumor necrosis-α in apoptotic death of bone marrow cells in myelodysplastic syndromes
31. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment
32. Serum erythropoietin concentrations in patients with myelodysplastic syndromes
33. Clinical application of recombinant erythropoietin in myelodysplasia
34. The use of rHuEpo in the treatment of anemia related to myelodysplasia (MDS)
35. Efficacy of erythropoietin in the myelodysplastic syndromes. A meta-analysis of 205 patients from 17 studies
36. Detection of antierythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin
37. Antibodies to recombinant human erythropoientin causing pure red cell aplasia
38. Relationship between autoantibody and dermatosis in myelodysplastic syndrome
39. Immunological abnormalities in myelodysplastic syndromes I. Serum immunoglobulins and autoantibodies
40. Autoimmune hemolytic anemia and myelodysplastic syndromes
41. Immunohematologic study in 112 patients with myelodysplastic syndromes: 10-year analysis
42. Malignant lymphoma complicating myelodysplastic syndrome with autoantibody for the thyroid gland
43. Crescentic glomerulonephritis accompanied by myeloperoxidase-antineutrophil cytoplasmic antibodies in a patient having myelodysplastic syndrome with trisomy 7
44. Low incidence Of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy
45. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients
46. Two cases of myelodysplastic syndrome with extramedullary polyclonal plasma cell proliferation and autonatibody production: Possible role of soluble Fas antigen for production of excessive self-reactive B cells